Patient-Reported Data Strengthen Case for Dato-DXd in First-Line TNBC Megan Brooks May 11, 2026

https://www.medscape.com/viewarticle/patient-reported-data-strengthen-case-dato-dxd-first-line-2026a1000f34 First-line datopotamab deruxtecan (Dato-DXd) not only improved survival outcomes vs chemotherapy but also delivered sustained quality-of-life benefits (QoL) for patients with locally recurrent, inoperable, or metastatic triple-negative breast cancer (TNBC) who were not candidates for immunotherapy in the TROPION-Breast02 study. https://www.medscape.com/c25/p14/esmo-breast-cancer-2026-2026a1000c6q